J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS)
INR 1934.75
(4.25%)
INR 1934.75
(4.25%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 9.33 Billion INR | -68.85% |
| 2022 | 7.04 Billion INR | 428.44% |
| 2021 | 5.81 Billion INR | -4.31% |
| 2020 | 6.72 Billion INR | 46.64% |
| 2019 | 4.18 Billion INR | 25.02% |
| 2018 | 3.46 Billion INR | 37.08% |
| 2017 | 2.53 Billion INR | -19.06% |
| 2016 | 2.8 Billion INR | 16.62% |
| 2015 | 2.64 Billion INR | 27.97% |
| 2014 | 1.91 Billion INR | 2.72% |
| 2013 | 1.21 Billion INR | 38.65% |
| 2012 | 1.33 Billion INR | -15.17% |
| 2011 | 8.75 Billion INR | -21.83% |
| 2010 | 1.95 Billion INR | 17.08% |
| 2009 | 1.78 Billion INR | 195.05% |
| 2008 | 574.94 Million INR | -5.11% |
| 2007 | 605.9 Million INR | -26.55% |
| 2006 | 824.92 Million INR | -11.71% |
| 2005 | 934.33 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.8 Billion INR | 33.3% |
| 2023 Q1 | 2.37 Billion INR | -89.71% |
| 2023 Q4 | 1.98 Billion INR | -14.04% |
| 2023 Q2 | 2.51 Billion INR | 5.66% |
| 2023 Q3 | 2.3 Billion INR | -8.25% |
| 2023 FY | - INR | -68.85% |
| 2022 Q3 | 1.77 Billion INR | -4.31% |
| 2022 Q1 | 1.73 Billion INR | 37.09% |
| 2022 FY | - INR | 428.44% |
| 2022 Q4 | 23.1 Billion INR | 1198.59% |
| 2022 Q2 | 1.85 Billion INR | 7.07% |
| 2021 Q4 | 1.26 Billion INR | -4.5% |
| 2021 Q3 | 1.32 Billion INR | -9.39% |
| 2021 Q2 | 1.46 Billion INR | -17.14% |
| 2021 Q1 | 1.76 Billion INR | 122.01% |
| 2021 FY | - INR | -4.31% |
| 2020 FY | - INR | 46.64% |
| 2020 Q2 | 1.18 Billion INR | -33.47% |
| 2020 Q3 | 1.93 Billion INR | 63.1% |
| 2020 Q4 | 795.72 Million INR | -58.83% |
| 2020 Q1 | 1.78 Billion INR | 110.04% |
| 2019 Q1 | 1.08 Billion INR | 35.03% |
| 2019 Q2 | 1.18 Billion INR | 9.38% |
| 2019 Q4 | 847.99 Million INR | -19.98% |
| 2019 FY | - INR | 25.02% |
| 2019 Q3 | 1.05 Billion INR | -10.77% |
| 2018 Q3 | 937.97 Million INR | 4.16% |
| 2018 Q2 | 900.55 Million INR | 19.73% |
| 2018 Q1 | 752.18 Million INR | 0.0% |
| 2018 FY | - INR | 37.08% |
| 2018 Q4 | 804.14 Million INR | -14.27% |
| 2017 Q1 | 403.39 Million INR | -32.36% |
| 2017 FY | - INR | -19.06% |
| 2016 FY | - INR | 16.62% |
| 2016 Q4 | 596.37 Million INR | 0.0% |
| 2015 FY | - INR | 27.97% |
| 2015 Q4 | 757.55 Million INR | 0.0% |
| 2014 FY | - INR | 2.72% |
| 2013 Q1 | 364.61 Million INR | 0.0% |
| 2013 FY | - INR | 38.65% |
| 2012 Q1 | 130.64 Million INR | 0.0% |
| 2012 FY | - INR | -15.17% |
| 2011 FY | - INR | -21.83% |
| 2010 FY | - INR | 17.08% |
| 2009 FY | - INR | 195.05% |
| 2008 FY | - INR | -5.11% |
| 2007 FY | - INR | -26.55% |
| 2006 FY | - INR | -11.71% |
| 2005 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sigachi Industries Limited | 883.39 Million INR | -956.694% |
| Ind-Swift Limited | 1.06 Billion INR | -776.454% |
| Bajaj HealthCare Limited | 406.23 Million INR | -2197.868% |
| Sakar Healthcare Limited | 393.26 Million INR | -2273.651% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 84.892% |
| Innova Captab Limited | 1.66 Billion INR | -459.537% |
| Divi's Laboratories Limited | 25.43 Billion INR | 63.292% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -296.08% |
| Morepen Laboratories Limited | 1.72 Billion INR | -440.849% |
| Mankind Pharma Limited | 28.09 Billion INR | 66.774% |
| Sequent Scientific Limited | 549.8 Million INR | -1597.856% |
| Wanbury Limited | 985.49 Million INR | -847.225% |
| Laurus Labs Limited | 8 Billion INR | -16.598% |
| Nectar Lifesciences Limited | 1.53 Billion INR | -507.897% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -36.019% |
| Alembic Limited | 1.11 Billion INR | -736.198% |
| Hikal Limited | 2.69 Billion INR | -246.732% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 2.931% |
| Neuland Laboratories Limited | 4.74 Billion INR | -96.597% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 17.709% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -258.122% |
| Themis Medicare Limited | 562.6 Million INR | -1559.206% |
| RPG Life Sciences Limited | 1.28 Billion INR | -628.428% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 83.397% |
| Lupin Limited | 36.96 Billion INR | 74.75% |
| Amrutanjan Health Care Limited | 681.59 Million INR | -1269.552% |
| Wockhardt Limited | 1.08 Billion INR | -764.334% |
| Vaishali Pharma Limited | 31.71 Million INR | -29337.139% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -138.777% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -2785.924% |
| Jubilant Pharmova Limited | 8 Billion INR | -16.598% |
| FDC Limited | 3.38 Billion INR | -175.74% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 89.425% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -3147.738% |
| Eris Lifesciences Limited | 6.98 Billion INR | -33.613% |
| Venus Remedies Limited | 711.8 Million INR | -1211.435% |
| ZIM Laboratories Limited | 462.09 Million INR | -1920.098% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -531.144% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -3991.093% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | -50.956% |
| Shilpa Medicare Limited | 2.58 Billion INR | -260.698% |
| Albert David Limited | 1.04 Billion INR | -792.922% |
| Ajanta Pharma Limited | 12.56 Billion INR | 25.71% |
| Hester Biosciences Limited | 539.47 Million INR | -1630.367% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -99.582% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 430.799% |
| Gufic Biosciences Limited | 1.48 Billion INR | -530.523% |
| Windlas Biotech Limited | 781.72 Million INR | -1094.137% |
| Procter & Gamble Health Limited | 3.07 Billion INR | -203.63% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -20568.241% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -5235.824% |
| Granules India Limited | 8.6 Billion INR | -8.496% |
| Aarti Drugs Limited | 3.24 Billion INR | -187.346% |
| Bal Pharma Limited | 345.59 Million INR | -2601.107% |
| Alkem Laboratories Limited | 24.19 Billion INR | 61.419% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 93.253% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | -594.905% |
| Medicamen Biotech Limited | 245.66 Million INR | -3699.89% |
| Unichem Laboratories Limited | 742.35 Million INR | -1157.457% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -8046.768% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -71728.339% |
| Valiant Laboratories Limited | 12.73 Million INR | -73177.424% |
| Orchid Pharma Limited | 1.41 Billion INR | -557.761% |
| Medico Remedies Limited | 129.09 Million INR | -7131.018% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -36.044% |
| Ipca Laboratories Limited | 13.29 Billion INR | 29.811% |
| Brooks Laboratories Limited | 41.72 Million INR | -22270.617% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -2069.494% |
| Piramal Enterprises Limited | -3.86 Billion INR | 341.766% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 73.337% |
| NATCO Pharma Limited | 18.79 Billion INR | 50.334% |
| Suven Life Sciences Limited | -992.78 Million INR | 1040.27% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 11383.875% |
| Strides Pharma Science Limited | 3.76 Billion INR | -147.958% |
| Indoco Remedies Limited | 2.64 Billion INR | -252.649% |
| Alpa Laboratories Limited | 229.96 Million INR | -3959.302% |
| Lasa Supergenerics Limited | -65.08 Million INR | 14443.594% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 350.165% |